National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 7) (Cth)

Case

PB 80 of 2023

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023
(No. 7)

National Health Act 1953

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated               30 August 2023                    

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1......... Name............................................................................................................................... 1

2......... Commencement............................................................................................................... 1

3......... Authority......................................................................................................................... 1

4......... Schedules......................................................................................................................... 1

Schedule 1—Amendments  2

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015).   2

  1. Name

(1)This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2023 (No. 7).

(2)This instrument may also be cited as PB 80 of 2023.

  1. Commencement

(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1 Column 2 Column 3
Provisions Commencement Date/Details
1. The whole of this instrument 1 September 2023 1 September 2023

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

  1. Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4        Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

  1. Schedule 1, after entry for Adalimumab in the form Injection 80 mg in 0.8 mL pre-filled syringe [Maximum Quantity: 3; Number of
    Repeats: 0]

insert:

Adapalene with benzoyl peroxide Gel 1 mg-25 mg per g, 30 g 20 2 3

  1. Schedule 1, entry for Alendronic acid

substitute:

Alendronic acid Tablet 70 mg (as alendronate sodium) 20 4 5
20 8 5

  1. Schedule 1, entry for Allopurinol

substitute:

Allopurinol Tablet 100 mg 20 200 2
20 400 2
Tablet 300 mg 20 60 2
20 120 2

  1. Schedule 1, entry for Amlodipine

substitute:

Amlodipine Tablet 5 mg (as besilate) 20 30 5
20 60 5
Tablet 10 mg (as besilate) 20 30 5
20 60 5

  1. Schedule 1, entry for Amlodipine with atorvastatin

substitute:

Amlodipine with atorvastatin Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) 20 30 5
20 60 5
Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) 20 30 5
20 60 5
Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) 20 30 5
20 60 5
Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) 20 30 5
20 60 5
Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) 20 30 5
20 60 5
Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) 20 30 5
20 60 5
Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) 20 30 5
20 60 5
Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) 20 30 5

  1. Schedule 1, entry for Amlodipine with valsartan

substitute:

Amlodipine with valsartan Tablet 5 mg (as besilate)‑80 mg 20 28 5
20 56 5
Tablet 5 mg (as besilate)‑160 mg 20 28 5
20 56 5
Tablet 5 mg (as besilate)‑320 mg 20 28 5
20 56 5
Tablet 10 mg (as besilate)‑160 mg 20 28 5
20 56 5
Tablet 10 mg (as besilate)‑320 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Amlodipine with valsartan and hydrochlorothiazide

substitute:

Amlodipine with valsartan and hydrochlorothiazide Tablet 5 mg (as besilate)‑160 mg‑12.5 mg 20 28 5
20 56 5
Tablet 5 mg (as besilate)‑160 mg‑25 mg 20 28 5
20 56 5
Tablet 10 mg (as besilate)‑160 mg‑12.5 mg 20 28 5
20 56 5
Tablet 10 mg (as besilate)‑160 mg‑25 mg 20 28 5
20 56 5
Tablet 10 mg (as besilate)‑320 mg‑25 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Apixaban

substitute:

Apixaban Tablet 2.5 mg 20 60 0
20 60 5
20 120 5
Tablet 5 mg 20 28 0
20 60 5
20 120 5

  1. Schedule 1, entry for Atenolol

substitute:

Atenolol Oral solution 50 mg in 10 mL, 300 mL 20 1 5
20 2 5
Tablet 50 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Atorvastatin

substitute:

Atorvastatin Tablet 10 mg (as calcium) 20 30 5
20 30 11
20 60 5
Tablet 20 mg (as calcium) 20 30 5
20 30 11
20 60 5
Tablet 40 mg (as calcium) 20 30 5
20 30 11
20 60 5
Tablet 80 mg (as calcium) 20 30 5
20 30 11
20 60 5

  1. Schedule 1, after entry for Auranofin in the form Tablet 3 mg

insert:

Azacitidine Tablet 200 mg 20 14 2
Tablet 300 mg 20 14 2
20 21 1

  1. Schedule 1, entry for Baclofen

substitute:

Baclofen Tablet 10 mg 20 100 5
20 200 5
Tablet 25 mg 20 100 5
20 200 5

  1. Schedule 1, entry for Balsalazide

substitute:

Balsalazide Capsule containing balsalazide sodium 750 mg 20 280 5
20 560 5

  1. Schedule 1, entry for Bisoprolol

substitute:

Bisoprolol Tablet containing bisoprolol fumarate 2.5 mg 20 28 5
20 56 5
Tablet containing bisoprolol fumarate 5 mg 20 28 5
20 56 5
Tablet containing bisoprolol fumarate 10 mg 20 28 5
20 56 5

  1. Schedule 1, after entry for Cabozantinib in the form Tablet 60 mg [Maximum Quantity: 30; Number of Repeats: 5]

insert:

Calcipotriol with betamethasone Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g 20 2 1
Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g 20 2 1

  1. Schedule 1, entry for Calcitriol

substitute:

Calcitriol Capsule 0.25 microgram 20 100 3
20 200 3

  1. Schedule 1, entry for Calcium

substitute:

Calcium Tablet, chewable, 500 mg (as carbonate) 20 480 1
Tablet 600 mg (as carbonate) 20 240 1
20 480 1

  1. Schedule 1, entry for Candesartan

substitute:

Candesartan Tablet containing candesartan cilexetil 4 mg 20 30 5
20 60 5
Tablet containing candesartan cilexetil 8 mg 20 30 5
20 60 5
Tablet containing candesartan cilexetil 16 mg 20 30 5
20 60 5
Tablet containing candesartan cilexetil 32 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Candesartan with hydrochlorothiazide

substitute:

Candesartan with hydrochlorothiazide Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg 20 30 5
20 60 5
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg 20 30 5
20 60 5
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Carvedilol

substitute:

Carvedilol Tablet 6.25 mg 20 60 5
20 120 5
Tablet 12.5 mg 20 60 5
20 120 5
Tablet 25 mg 20 60 5
20 120 5

  1. Schedule 1, after entry for Certolizumab pegol in the form Solution for injection 200 mg in 1 mL pre-filled pen

insert:

Chlortalidone Tablet 25 mg 20 200 1

  1. Schedule 1, entry for Clonidine

substitute:

Clonidine Tablet containing clonidine hydrochloride 100 micrograms 20 100 5
20 200 5
Tablet containing clonidine hydrochloride 150 micrograms 20 100 5
20 200 5

  1. Schedule 1, entry for Clopidogrel

substitute:

Clopidogrel Tablet 75 mg (as besilate) 20 28 5
20 56 5
Tablet 75 mg (as hydrogen sulfate) 20 28 5
20 56 5

  1. Schedule 1, entry for Clopidogrel with aspirin

substitute:

Clopidogrel with aspirin Tablet 75 mg (as hydrogen sulfate)‑100 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Dabigatran etexilate

substitute:

Dabigatran etexilate Capsule 75 mg (as mesilate) 20 60 0
Capsule 110 mg (as mesilate) 20 60 0
20 60 5
20 120 5
Capsule 150 mg (as mesilate) 20 60 5
20 120 5

  1. Schedule 1, entry for Enalapril

substitute:

Enalapril Tablet containing enalapril maleate 5 mg 20 30 5
20 60 5
Tablet containing enalapril maleate 10 mg 20 30 5
20 60 5
Tablet containing enalapril maleate 20 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Enalapril with hydrochlorothiazide

substitute:

Enalapril with hydrochlorothiazide Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Eplerenone

substitute:

Eplerenone Tablet 25 mg 20 30 5
20 60 5
Tablet 50 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Ezetimibe

substitute:

Ezetimibe Tablet 10 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Ezetimibe and rosuvastatin

substitute:

Ezetimibe and rosuvastatin Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) 20 1 5
20 2 5
Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) 20 1 5
20 2 5
Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) 20 1 5
20 2 5
Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) 20 1 5
20 2 5

  1. Schedule 1, entry for Ezetimibe with atorvastatin

substitute:

Ezetimibe with atorvastatin Tablet 10 mg‑10 mg 20 30 5
20 60 5
Tablet 10 mg‑20 mg 20 30 5
20 60 5
Tablet 10 mg‑40 mg 20 30 5
20 60 5
Tablet 10 mg‑80 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Ezetimibe with simvastatin

substitute:

Ezetimibe with simvastatin Tablet 10 mg‑10 mg 20 30 5
20 60 5
Tablet 10 mg‑20 mg 20 30 5
20 60 5
Tablet 10 mg‑40 mg 20 30 5
20 60 5
Tablet 10 mg‑80 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Febuxostat

substitute:

Febuxostat Tablet 80 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Felodipine

substitute:

Felodipine Tablet 2.5 mg (extended release) 20 30 5
20 60 5
Tablet 5 mg (extended release) 20 30 5
20 60 5
Tablet 10 mg (extended release) 20 30 5
20 60 5

  1. Schedule 1, entry for Fenofibrate

substitute:

Fenofibrate Tablet 48 mg 20 60 5
20 60 11
20 120 5
Tablet 145 mg 20 30 5
20 30 11
20 60 5

  1. Schedule 1, entry for Fluvastatin

substitute:

Fluvastatin Tablet (prolonged release) 80 mg (as sodium) 20 28 5
20 28 11
20 56 5

  1. Schedule 1, entry for Furosemide

substitute:

Furosemide Oral solution 10 mg per mL, 30 mL 20 2 3
Tablet 20 mg 20 100 1
20 200 1
Tablet 40 mg 20 100 1
20 200 1
Tablet 500 mg 20 100 3

  1. Schedule 1, entry for Gemfibrozil

substitute:

Gemfibrozil Tablet 600 mg 20 60 5
20 60 11
20 120 5

  1. Schedule 1, entry for Glyceryl trinitrate

substitute:

Glyceryl trinitrate Sublingual spray (pump pack) 400 micrograms per dose, 200 doses 20 2 5
Transdermal patch 18 mg 20 30 5
Transdermal patch 25 mg 20 30 5
20 60 5
Transdermal patch 36 mg 20 30 5
Transdermal patch 50 mg 20 30 5
20 60 5
Transdermal patch 54 mg 20 30 5

  1. Schedule 1, entry for Hydrochlorothiazide

substitute:

Hydrochlorothiazide Tablet 25 mg 20 100 1
20 200 1

  1. Schedule 1, entry for Hydrochlorothiazide with amiloride

substitute:

Hydrochlorothiazide with amiloride Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg 20 100 1
20 200 1

  1. Schedule 1, entry for Indapamide

substitute:

Indapamide Tablet containing indapamide hemihydrate 1.5 mg (sustained release) 20 90 1
20 180 1
Tablet containing indapamide hemihydrate 2.5 mg 20 90 1
20 180 1

  1. Schedule 1, entry for Irbesartan

substitute:

Irbesartan Tablet 75 mg 20 30 5
20 60 5
Tablet 150 mg 20 30 5
20 60 5
Tablet 300 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Irbesartan with hydrochlorothiazide

substitute:

Irbesartan with hydrochlorothiazide Tablet 150 mg‑12.5 mg 20 30 5
20 60 5
Tablet 300 mg‑12.5 mg 20 30 5
20 60 5
Tablet 300 mg‑25 mg 20 30 5
20 60 5

  1. Schedule 1, after entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 60; Number of Repeats: 5]

insert:

Isosorbide dinitrate Tablet 5 mg (sublingual) 20 400 2

  1. Schedule 1, entry for Isosorbide mononitrate

substitute:

Isosorbide mononitrate Tablet 60 mg (sustained release) 20 30 5
20 60 5
Tablet 120 mg (sustained release) 20 30 5
20 60 5

  1. Schedule 1, entry for Lercanidipine

substitute:

Lercanidipine Tablet containing lercanidipine hydrochloride 10 mg 20 28 5
20 56 5
Tablet containing lercanidipine hydrochloride 20 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Lercanidipine with enalapril

substitute:

Lercanidipine with enalapril Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg 20 28 5
20 56 5
Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Lisinopril

substitute:

Lisinopril Tablet 5 mg 20 30 5
20 60 5
Tablet 10 mg 20 30 5
20 60 5
Tablet 20 mg 20 30 5
20 60 5

  1. Schedule 1, omit entry for Losartan

  1. Schedule 1, entry for Mesalazine

substitute:

Mesalazine Sachet containing granules, 500 mg per sachet 20 200 5
20 400 5
Sachet containing granules, 1 g per sachet 20 100 5
20 200 5
Sachet containing granules, 1.5 g per sachet 20 60 5
20 120 5
Sachet containing granules, 3 g per sachet 20 30 5
20 60 5
Sachet containing prolonged release granules, 1 g per sachet 20 100 5
20 200 5
Sachet containing prolonged release granules, 2 g per sachet 20 60 5
20 120 5
Sachet containing prolonged release granules, 4 g per sachet 20 30 5
20 60 5
Tablet 250 mg (enteric coated) 20 100 5
20 200 5
Tablet 500 mg (enteric coated) 20 200 5
20 400 5
Tablet 500 mg (prolonged release) 20 200 5
20 400 5
Tablet 800 mg (enteric coated) 20 90 5
20 180 5
Tablet 1 g (enteric coated) 20 120 5
20 240 5
Tablet 1 g (prolonged release) 20 120 5
20 240 5
Tablet 1.2 g (prolonged release) 20 120 5
20 240 5
Tablet 1.6 g (enteric coated) 20 120 4
20 240 4

  1. Schedule 1, entry for Metoprolol

substitute:

Metoprolol Tablet containing metoprolol tartrate 50 mg 20 100 5
20 200 5
Tablet containing metoprolol tartrate 100 mg 20 60 5
20 120 5

  1. Schedule 1, entry for Metoprolol succinate

substitute:

Metoprolol succinate Tablet 47.5 mg (controlled release) 20 30 5
20 60 5
Tablet 95 mg (controlled release) 20 30 5
20 60 5
Tablet 190 mg (controlled release) 20 30 5
20 60 5

  1. Schedule 1, entry for Moxonidine

substitute:

Moxonidine Tablet 200 micrograms 20 30 5
20 60 5
Tablet 400 micrograms 20 30 5
20 60 5

  1. Schedule 1, entry for Nebivolol

substitute:

Nebivolol Tablet 1.25 mg (as hydrochloride) 20 56 5
20 112 5
Tablet 5 mg (as hydrochloride) 20 28 5
20 56 5
Tablet 10 mg (as hydrochloride) 20 28 5
20 56 5

  1. Schedule 1, entry for Nicorandil

substitute:

Nicorandil Tablets 10 mg, 60 20 1 5
20 2 5
Tablets 20 mg, 60 20 1 5
20 2 5

  1. Schedule 1, entry for Nifedipine

substitute:

Nifedipine Tablet 30 mg (controlled release) 20 30 5
20 60 5
Tablet 60 mg (controlled release) 20 30 5
20 60 5

  1. Schedule 1, omit entry for Norethisterone with mestranol

  1. Schedule 1, entry for Olmesartan

substitute:

Olmesartan Tablet containing olmesartan medoxomil 20 mg 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Olmesartan with amlodipine

substitute:

Olmesartan with amlodipine Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) 20 30 5
Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) 20 30 5

  1. Schedule 1, entry for Olmesartan with amlodipine and hydrochlorothiazide

substitute:

Olmesartan with amlodipine and hydrochlorothiazide Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg 20 30 5

  1. Schedule 1, entry for Olmesartan with hydrochlorothiazide

substitute:

Olmesartan with hydrochlorothiazide Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg 20 30 5
20 60 5
Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Ozanimod

substitute:

Ozanimod Capsule 920 micrograms 20 28 3
20 28 5
Pack containing 4 capsules 230 micrograms and 3 capsules
460 micrograms 		20 1 0

  1. Schedule 1, after entry for Palbociclib in the form Tablet 125 mg

insert:

Pancreatic extract Capsule (containing enteric coated minimicrospheres) providing not less than 10,000 BP units of lipase activity 20 1000 10
Capsule (containing enteric coated minimicrospheres) providing not less than 25,000 BP units of lipase activity 20 400 10
Capsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activity 20 400 10
Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g 20 6 10

  1. Schedule 1, after entry for Paroxetine

insert:

Patiromer Powder for oral suspension 8.4 g 20 30 5
Powder for oral suspension 16.8 g 20 30 5

  1. Schedule 1, after entry for Pazopanib in the form Tablet 400 mg (as hydrochloride) [Maximum Quantity: 60; Number of Repeats: 5]

insert:

Penicillamine Tablet 125 mg 20 200 1
Tablet 250 mg 20 200 1

  1. Schedule 1, entry for Perindopril

substitute:

Perindopril Tablet containing perindopril arginine 2.5 mg 20 30 5
20 60 5
Tablet containing perindopril arginine 5 mg 20 30 5
20 60 5
Tablet containing perindopril arginine 10 mg 20 30 5
20 60 5
Tablet containing perindopril erbumine 2 mg 20 30 5
20 60 5
Tablet containing perindopril erbumine 4 mg 20 30 5
20 60 5
Tablet containing perindopril erbumine 8 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Perindopril with amlodipine

substitute:

Perindopril with amlodipine Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) 20 30 5
20 60 5
Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) 20 30 5
20 60 5
Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) 20 30 5
20 60 5
Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) 20 30 5
20 60 5

  1. Schedule 1, entry for Perindopril with indapamide

substitute:

Perindopril with indapamide Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg 20 30 5
20 60 5
Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg 20 30 5
20 60 5
Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Potassium chloride

substitute:

Potassium chloride Tablet 600 mg (sustained release) 20 200 1
20 400 1

  1. Schedule 1, entry for Potassium chloride with potassium bicarbonate

substitute:

Potassium chloride with potassium bicarbonate Tablet, effervescent, 14 mmol potassium and 8 mmol chloride 20 60 1
20 120 1

  1. Schedule 1, entry for Pravastatin

substitute:

Pravastatin Tablet containing pravastatin sodium 10 mg 20 30 5
20 30 11
20 60 5
Tablet containing pravastatin sodium 20 mg 20 30 5
20 30 11
20 60 5
Tablet containing pravastatin sodium 40 mg 20 30 5
20 30 11
20 60 5
Tablet containing pravastatin sodium 80 mg 20 30 5
20 30 11
20 60 5

  1. Schedule 1, entry for Prazosin

substitute:

Prazosin Tablet 1 mg (as hydrochloride) 20 100 5
20 200 5
Tablet 2 mg (as hydrochloride) 20 100 5
20 200 5
Tablet 5 mg (as hydrochloride) 20 100 5
20 200 5

  1. Schedule 1, entry for Propranolol

substitute:

Propranolol Tablet containing propranolol hydrochloride 10 mg 20 100 5
20 200 5
Tablet containing propranolol hydrochloride 40 mg 20 100 5
20 200 5

  1. Schedule 1, entry for Raloxifene

substitute:

Raloxifene Tablet containing raloxifene hydrochloride 60 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Ramipril

substitute:

Ramipril Capsule 1.25 mg 20 30 5
20 60 5
Capsule 2.5 mg 20 30 5
20 60 5
Capsule 5 mg 20 30 5
20 60 5
Capsule 10 mg 20 30 5
20 60 5
Tablet 1.25 mg 20 30 5
20 60 5
Tablet 2.5 mg 20 30 5
20 60 5
Tablet 5 mg 20 30 5
20 60 5
Tablet 10 mg 20 30 5
20 60 5

  1. Schedule 1, entry for Ramipril with felodipine

substitute:

Ramipril with felodipine Tablet 2.5 mg‑2.5 mg (modified release) 20 30 5
20 60 5
Tablet 5 mg‑5 mg (modified release) 20 30 5
20 60 5

  1. Schedule 1, entry for Risedronic acid

substitute:

Risedronic acid Tablet containing risedronate sodium 5 mg 20 28 5
20 56 5
Tablet containing risedronate sodium 30 mg 20 28 1
Tablet containing risedronate sodium 35 mg 20 4 5
20 8 5
Tablet containing risedronate sodium 150 mg 20 1 5
20 2 5
Tablet (enteric coated) containing risedronate sodium 35 mg 20 4 5
20 8 5

  1. Schedule 1, entry for Rivaroxaban

substitute:

Rivaroxaban Tablet 2.5 mg 20 60 5
20 120 5
Tablet 10 mg 20 30 5
20 60 5
Tablet 15 mg 20 28 5
20 56 5
Tablet 20 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Rosuvastatin

substitute:

Rosuvastatin Tablet 5 mg (as calcium) 20 30 5
20 30 11
20 60 5
Tablet 10 mg (as calcium) 20 30 5
20 30 11
20 60 5
Tablet 20 mg (as calcium) 20 30 5
20 30 11
20 60 5
Tablet 40 mg (as calcium) 20 30 5
20 30 11
20 60 5

  1. Schedule 1, entry for Sacubitril with valsartan

substitute:

Sacubitril with valsartan Tablet containing sacubitril 24.3 mg with valsartan 25.7 mg 20 56 5
20 112 5
Tablet containing sacubitril 48.6 mg with valsartan 51.4 mg 20 56 5
20 112 5
Tablet containing sacubitril 97.2 mg with valsartan 102.8 mg 20 56 5
20 112 5

  1. Schedule 1, entry for Simvastatin

substitute:

Simvastatin Tablet 5 mg 20 30 5
20 30 11
20 60 5
Tablet 10 mg 20 30 5
20 30 11
20 60 5
Tablet 20 mg 20 30 5
20 30 11
20 60 5
Tablet 40 mg 20 30 5
20 30 11
20 60 5
Tablet 80 mg 20 30 5
20 30 11
20 60 5

  1. Schedule 1, entry for Spironolactone

substitute:

Spironolactone Tablet 25 mg 20 100 5
20 200 5
Tablet 100 mg 20 100 5

  1. Schedule 1, entry for Sulfasalazine

substitute:

Sulfasalazine Tablet 500 mg 20 200 5
20 200 11
20 400 5
Tablet 500 mg (enteric coated) 20 200 5
20 200 11
20 400 5

  1. Schedule 1, entry for Telmisartan

substitute:

Telmisartan Tablet 40 mg 20 28 5
20 56 5
Tablet 80 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Telmisartan with amlodipine

substitute:

Telmisartan with amlodipine Tablet 40 mg‑5 mg (as besilate) 20 28 5
20 56 5
Tablet 40 mg‑10 mg (as besilate) 20 28 5
20 56 5
Tablet 80 mg‑5 mg (as besilate) 20 28 5
20 56 5
Tablet 80 mg‑10 mg (as besilate) 20 28 5
20 56 5

  1. Schedule 1, entry for Telmisartan with hydrochlorothiazide

substitute:

Telmisartan with hydrochlorothiazide Tablet 40 mg‑12.5 mg 20 28 5
20 56 5
Tablet 80 mg‑12.5 mg 20 28 5
20 56 5
Tablet 80 mg‑25 mg 20 28 5
20 56 5

  1. Schedule 1, after entry for Theophylline in the form Tablet 300 mg (sustained release)

insert:

Thiamine Tablet containing thiamine hydrochloride 100 mg 20 200 2

  1. Schedule 1, entry for Ticagrelor

substitute:

Ticagrelor Tablet 90 mg 20 56 5
20 112 5

  1. Schedule 1, entry for Trandolapril

substitute:

Trandolapril Capsule 500 micrograms 20 28 5
20 56 5
Capsule 1 mg 20 28 5
20 56 5
Capsule 2 mg 20 28 5
20 56 5
Capsule 4 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Trandolapril with verapamil

substitute:

Trandolapril with verapamil Tablet containing trandolapril 2 mg with verapamil hydrochloride 180 mg (sustained release) 20 28 5
20 56 5
Tablet containing trandolapril 4 mg with verapamil hydrochloride 240 mg (sustained release) 20 28 5
20 56 5

  1. Schedule 1, entry for Valsartan

substitute:

Valsartan Tablet 80 mg 20 28 5
20 56 5
Tablet 160 mg 20 28 5
20 56 5
Tablet 320 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Valsartan with hydrochlorothiazide

substitute:

Valsartan with hydrochlorothiazide Tablet 80 mg‑12.5 mg 20 28 5
20 56 5
Tablet 160 mg‑12.5 mg 20 28 5
20 56 5
Tablet 160 mg‑25 mg 20 28 5
20 56 5
Tablet 320 mg‑12.5 mg 20 28 5
20 56 5
Tablet 320 mg‑25 mg 20 28 5
20 56 5

  1. Schedule 1, entry for Verapamil

substitute:

Verapamil Tablet containing verapamil hydrochloride 80 mg 20 100 5
20 200 5
Tablet containing verapamil hydrochloride 180 mg (sustained release) 20 30 5
20 60 5
Tablet containing verapamil hydrochloride 240 mg (sustained release) 20 30 5
20 60 5
Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0